MPN Hub

Celková doba trvání:3 h 45 min

	Novel treatments: Momelotinib and luspatercept	MPN Hub	32:21
	Anemia in myelofibrosis: Q&A	MPN Hub	14:42
	Symposium \| Sequencing therapies: Optimizing treatment for myelofibrosis	MPN Hub	15:32
	Symposium \| The treatment landscape for patients with myelofibrosis and anemia	MPN Hub	14:45
	Symposium \| Anemia in myelofibrosis: Impact on patient outcomes	MPN Hub	06:56
	Anemia as an unmet need: Impacts on QoL and survival outcomes	MPN Hub	12:02
	Clinical trial round-up: Treating anemia in patients with myelofibrosis	MPN Hub	06:34
	How might luspatercept benefit patients with myelofibrosis?	MPN Hub	08:00
	What more can be done to improve treatment for patients with polycythemia vera?	MPN Hub	06:10
	When to refer patients with MPN to clinical trials: Part II - Patients with MF	MPN Hub	15:07
	When to refer patients with MPN to clinical trials: Part I - Patients with ET/PV	MPN Hub	11:44
	Patient follow-up in myeloproliferative neoplasms: Best practices and myths	MPN Hub	14:03
	Is the hepcidin-mimetic PTG‑300 a promising treatment for therapeutic phlebotomy-dependent PV?	MPN Hub	08:25
	Should we consider early testing and treatment for driver mutations acquired in childhood?	MPN Hub	05:58
	When can we safely discontinue interferon alpha therapy in patients with MPN?	MPN Hub	04:57
	Does interferon alpha prolong survival and prevent progression in patients with PV?	MPN Hub	05:34
	What do we know about the outcome of concomitant MPN and COVID-19?	MPN Hub	17:43
	How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease	MPN Hub	24:34